Finsight Funds was established in order to bring a modern approach to the world of investing.
Through the meticulous use of data, coupled with the latest academic and proprietary research, Finsight Funds aims to efficiently beat an inefficient market. In our interconnected world of Big Data, it should be easier than ever to identify trends and forces shaping markets.
The manager of Finsight Funds began investing in the stock market more than 10 years ago. He has experience working on the buy-side for both a large asset management firm (which managed in excess of $50 billion) as well as a small hedge fund (AUM of $50m). He is now branching out through Finsight to develop a more modern approach to investing. He is a CFA Level 3 candidate for June 2017.
The purpose and mission for Finsight Funds is to help allocate financial resources where they can provide the most value to the world.
Part of the goal in writing for Seeking Alpha is to listen and understand the reactions of readers to the research, thoughts, and ideas that are presented.
"He who listens becomes the master of what is profitable."
For those concerned with my anonymity as Finsight Funds:
Recently, a reader voiced his concern to me about my anonymity. My response, which I feel is appropriate to share here, was:
"I have thought much about the distinction between myself as a PM and the institution I am founding; while I would love to have my institution accomplish a lot, I do not want resulting personal fame or attention. I would prefer to be out of the limelight. For those reasons, I have decided to promote the institution rather than myself."
Professional investor and overall good guy.
By reading Mako Research reports, you agree to use the information at your own risk. In no event should Mako Research or any affiliated party be liable for any direct or indirect trading losses caused by information contained in the research reports. Research reports are not investment advice or a recommendation or solicitation to transact any securities. Mako Research is not a registered investment advisor. You agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that Mako Research stands to profit in the event the issuer’s stock declines. Research reports may contain opinions, which are based upon generally available public information, field research, inferences and deductions through due diligence and analytical processes. All information is believed to be accurate and reliable, and has been obtained from public sources. Mako Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information. All expressions of opinion are subject to change without notice, and Mako Research is not obligated to update or supplement any reports or any of the information, analysis and opinion contained in them. You should assume that Mako Research has and/or will submit findings with the Securities Exchange Commission, and other entities that may find the information useful.
Born and raised in the USA, graduated with a degree in Finance then worked at a multi-strategy global hedge fund for about 4 years analyzing stocks all over the world. In 2007 I left the USA and moved to China to study Chinese and start a business. Now, I am the CEO and Co-founder of eFin which provides wall street level research to main street investors via a proprietary algorithm. Our eFin scoe that takes into consideration hundreds of factors to provide the best period of time to make an investment in a stock.
Nevertheless, my experience working at the hedge fund and running my own business has improved vastly my investment making decisions. I believe Warren Buffett said it best “I am a better investor because I am a businessman and a better businessman because I am an investor”. I have had my share of busts and winners and have gotten wise enough to always look at both sides of every investment no matter how negative or optimistic the situation is.
PLEASE SEE WEBSITE FOR FULL DISCLAIMER: WWW.PUMPSTOPPER.COM
I produce high quality, original research free of charge for the public good. Please see the website for more information, and subscribe to The Pump Stopper email list to receive free, high quality research reports before the rest.
I am always committed to publishing the accurate truth. If you are involved with a company that has been mentioned in a report and find any factual errors, please submit a dispute to Seeking Alpha and it will be reviewed.
If you have any tips on companies misleading investors, please submit them on The Pump Stopper website. I always welcome collaboration and have absolute respect for your anonymity. There are multiple ways to submit documents anonymously, as outlined on the website, and I strongly recommend you send information this way.
And remember to always invest wisely.
Demonstrated success is the one outstanding fact which justifies confidence in the outlook for any particular business, and thus the investor will always, as a first test for an industry security, carefully consider the results already obtained. John Moody
As an Editor on the SA PRO team my job is to help find the best content for PRO, to provide feedback and develop talented contributors, and to work with other departments to strengthen the platform.
I have studied to ply my trade in finance with a bachelors in accounting. In 2014, I developed an app to access corporate disclosure materials at the SEC. My grandparent’s home was filled with valuing investing paraphernalia and, naturally, I became interested in the stock market.
Seeking Alpha is full of hidden gems and bum steers. Check out some of the authors I follow. And authors, check out "The Elements of Style" by Strunk & White.
Stocktalks represent my personal opinion only - links are not endorsements.
I am a medical professional that enjoys investing in biotech stocks. I take long positions and may dabble in options. I have a particular interest in biotechs with an ophthalmic (eye) focus as that is where I have developed the greatest expertise over my career and research. I hope over time to share some of my professional insights with those of the Seeking Alpha community in order to help them make more informed investing decisions. I expect to learn a lot from others as well.
I am long the following biotechs at this time: GILD, OPHT, CRMD, ACAD, RLYP, HALO, TGTX, APHB, ZIOP.
I am advising everyone to avoid: OHRP